Preview

Кардиология

Расширенный поиск

Клиническая эффективность и механизмы действия агонистов рецепторов глюкагоноподобного пептида 1‑го типа у пациентов с сахарным диабетом 2‑го типа и высоким риском развития осложнений сердечно-сосудистых заболеваний

https://doi.org/10.18087/cardio.2021.4.n1549

Полный текст:

Аннотация

В статье обсуждаются проблемы снижения риска развития сердечно-сосудистых заболеваний (ССЗ) у пациентов с сахарным диабетом (СД) 2‑го типа при лечении современными гипогликемическими препаратами, в частности агонистами рецепторов глюкагоноподобного пептида 1‑го типа.

Об авторе

С. Р. Гиляревский
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РФ, Москва
Россия

кафедра клинической фаркмакологии и терапии им. Б.Е Вотчала

 



Список литературы

1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Research and Clinical Practice. 2019;157:107843. DOI: 10.1016/j.diabres.2019.107843

2. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. Journal of the American College of Cardiology. 2020;76(25):2982–3021. DOI: 10.1016/j.jacc.2020.11.010

3. American Diabetes Association. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes–2019. Diabetes Care. 2019;42(Suppl 1):S103–23. DOI: 10.2337/dc19-S010

4. The Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. The Lancet. 2010;375(9733):2215–22. DOI: 10.1016/S0140-6736(10)60484-9

5. Dugani SB, Moorthy MV, Li C, Demler OV, Alsheikh-Ali AA, Ridker PM et al. Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women. JAMA Cardiology. 2021; [Epub ahead of print]. DOI: 10.1001/jamacardio.2020.7073

6. Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–701. DOI: 10.2337/dci18-0033

7. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal. 2020;41(2):255–323. DOI: 10.1093/eurheartj/ehz486

8. Verma NK, Singh J, Dey CS. PPAR-γ expression modulates insulin sensitivity in C2C12 skeletal muscle cells. British Journal of Pharmacology. 2004;143(8):1006–13. DOI: 10.1038/sj.bjp.0706002

9. Kapadia R, Yi JH, Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Frontiers in Bioscience. 2008;13(13):1813–26. DOI: 10.2741/2802

10. Abbas A, Blandon J, Rude J, Elfar A, Mukherjee D. PPAR-γ Agonist in Treatment of Diabetes: Cardiovascular Safety Considerations. Cardiovascular & Hematological Agents in Medicinal Chemistry. 2012;10(2):124–34. DOI: 10.2174/187152512800388948

11. Kung J, Henry RR. Thiazolidinedione safety. Expert Opinion on Drug Safety. 2012;11(4):565–79. DOI: 10.1517/14740338.2012.691963

12. Flachs P, Rossmeisl M, Bryhn M, Kopecky J. Cellular and molecular effects of n−3 polyunsaturated fatty acids on adipose tissue biology and metabolism. Clinical Science. 2009;116(1):1–16. DOI: 10.1042/CS20070456

13. The ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H et al. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of Medicine. 2012;367(4):319–28. DOI: 10.1056/NEJMoa1203858

14. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. The New England Journal of Medicine. 2019;380(1):11–22. DOI: 10.1056/NEJMoa1812792

15. Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020;324(22):2268–80. DOI: 10.1001/jama.2020.22258

16. Levin PA, Wei W, Zhou S, Xie L, Baser O. Outcomes and Treatment Patterns of Adding a Third Agent to 2 OADs in Patients with Type 2 Diabetes. Journal of Managed Care Pharmacy. 2014;20(5):501–12. DOI: 10.18553/jmcp.2014.20.5.501

17. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine. 2019;381(21):1995–2008. DOI: 10.1056/NEJMoa1911303

18. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine. 2020;383(15):1413–24. DOI: 10.1056/NEJMoa2022190

19. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F et al. Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. 2020;383(15):1436–46. DOI: 10.1056/NEJMoa2024816

20. Nelson AJ, Ardissino M, Haynes K, Shambhu S, Eapen ZJ, McGuire DK et al. Gaps in Evidence‐Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease. Journal of the American Heart Association. 2021;10(2):e016835. DOI: 10.1161/JAHA.120.016835

21. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2016;375(4):311–22. DOI: 10.1056/NEJMoa1603827

22. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016;375(19):1834–44. DOI: 10.1056/NEJMoa1607141

23. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. 2019;394(10193):121–30. DOI: 10.1016/S0140-6736(19)31149-3

24. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. New England Journal of Medicine. 2015;373(23):2247–57. DOI: 10.1056/NEJMoa1509225

25. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2017;377(13):1228–39. DOI: 10.1056/NEJMoa1612917

26. Goldman JD. Cardiovascular safety outcomes of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes. Journal of Clinical Pharmacy and Therapeutics. 2020;45(S1):61–72. DOI: 10.1111/jcpt.13226

27. Kapitza C, Dahl K, Jacobsen JB, Axelsen MB, Flint A. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Diabetologia. 2017;60(8):1390–9. DOI: 10.1007/s00125-017-4289-0

28. Rakipovski G, Rolin B, Nøhr J, Klewe I, Frederiksen KS, Augustin R et al. The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways. JACC: Basic to Translational Science. 2018;3(6):844–57. DOI: 10.1016/j.jacbts.2018.09.004

29. Hansson GK, Libby P, Tabas I. Inflammation and plaque vulnerability. Journal of Internal Medicine. 2015;278(5):483–93. DOI: 10.1111/joim.12406

30. Libby P, Hansson GK. Inflammation and Immunity in Diseases of the Arterial Tree: Players and Layers. Circulation Research. 2015;116(2):307–11. DOI: 10.1161/CIRCRESAHA.116.301313

31. Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nature Reviews Drug Discovery. 2014;13(6):465–76. DOI: 10.1038/nrd4275

32. Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg SØ et al. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care. 2019;42(12):2272–81. DOI: 10.2337/dc19-0883

33. Zhuo X, Zhang C, Feng J, Ouyang S, Niu P, Dai Z. In-hospital, shortterm and long-term adverse clinical outcomes observed in patients with type 2 diabetes mellitus vs non-diabetes mellitus following percutaneous coronary intervention: A meta-analysis including 139,774 patients. Medicine. 2019;98(8):e14669. DOI: 10.1097/MD.0000000000014669

34. Xia J, Li Q, Liu Y, Ren Q, Gao J, Tian Y et al. A GLP-1 Analog Liraglutide Reduces Intimal Hyperplasia After Coronary Stent Implantation via Regulation of Glycemic Variability and NLRP3 Inflammasome/IL-10 Signaling in Diabetic Swine. Frontiers in Pharmacology. 2020;11:372. DOI: 10.3389/fphar.2020.00372

35. Hamal S, Cherukuri L, Shaikh K, Kinninger A, Doshi J, Birudaraju D et al. Effect of semaglutide on coronary atherosclerosis progression in patients with type II diabetes: rationale and design of the semaglutide treatment on coronary progression trial. Coronary Artery Disease. 2020;31(3):306–14. DOI: 10.1097/MCA.0000000000000830


Для цитирования:


Гиляревский С.Р. Клиническая эффективность и механизмы действия агонистов рецепторов глюкагоноподобного пептида 1‑го типа у пациентов с сахарным диабетом 2‑го типа и высоким риском развития осложнений сердечно-сосудистых заболеваний. Кардиология. 2021;61(4):66-72. https://doi.org/10.18087/cardio.2021.4.n1549

For citation:


Gilarevsky S.R. Clinical Efficacy and Mechanisms of Actions of the Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and High Risk of Cardiovascular Diseases. Kardiologiia. 2021;61(4):66-72. (In Russ.) https://doi.org/10.18087/cardio.2021.4.n1549

Просмотров: 148


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)